Sandoz gains backing for Enbrel patent term review
Sandoz, a subsidiary of Swiss pharmaceutical company Novartis, has gathered support for its request for an en banc rehearing of a ruling that blocks it from selling a version of biologic Enbrel (etanercept) until 2029.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 September 2026 A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
10 September 2026 Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.
7 September 2026 A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.
